CIK 0001534248 · Non-accelerated filer<br>Smaller reporting company
Chemomab Therapeutics Ltd.
Sign in to watch- Ticker
- CMMB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- EIN
- 813676773
- Phone
- 972-77-331-0156
- Business address
- KIRYAT ATIDIM, BUILDING 7, TEL AVIV, Israel
- Former names
- Anchiano Therapeutics Ltd., BioCancell Ltd.
- 4 Open-market sale Chief Scientific Officer sold 13,800 shares at $5.03 ($69,370)
- 4 Open-market sale Director sold 2,409 shares at $2.00 ($4,818)
- 4 Open-market sale Chief Scientific Officer sold 582,023 shares at $2.08 ($1,213,402)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Executive VP, CFO & COO bought 500 shares at an average $3.28 ($1,638)
- 4 Open-market buy Director bought 433 shares at an average $2.88 ($1,247)
- 4 Open-market buy Director bought 2,000 shares at $3.19 ($6,380)
- 4 Open-market buy Director bought 1,000 shares at an average $4.34 ($4,340)
- 4 Open-market buy Executive VP, CFO & COO bought 1,250 shares at an average $4.04 ($5,045)
- 4 Open-market buy Chief Executive Officer bought 2,500 shares at an average $3.98 ($9,943)
- 4 Open-market buy Director bought 6,000 shares at an average $4.35 ($26,120)
- 4 Open-market buy Director bought 1,200 shares at $4.28 ($5,136)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 2,000 shares at $7.43 ($14,860)
- 3 Insider Initial Statement of Ownership
Page 2 of 5 · 83 filings